Galectin Therapeutics (GALT) — AI Analysis & Mentions

Galectin Therapeutics has multiple insider-sale headlines in the feed, including a director and the CMO selling shares after option exercises. The sales were described as pre-planned or under a Rule 10b5-1 plan, which reduces the chance that they signal panic, but the overall tone is still cautious. When several insiders are reducing exposure, many investors will want to ask whether the business story is strong enough to justify the enthusiasm.